Depletion of METTL3 expression can further impede tumorigenicity and heighten the sensitivity of lung cancer cells to BRD4 inhibition, implicating METTL3 as a viable candidate for cancer therapeutics.123. This evidence concerns the gene METTL3 and lung cancer.